SCHEMBL4452612

SCHEMBL4452612

CCCOc1ccc(Nc2cc(OC3CCN(C(=O)OC(C)C)CC3)ncn2)c(F)c1F

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 19/20 0.66
CYP2C9 P11712 3/20 0.47
EGFR P00533 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL390233 0.89 GPR119 (0.66) GPR119CYP2C9
SCHEMBL389617 0.87 GPR119 (0.73) GPR119CYP2C9
SCHEMBL390039 0.83 GPR119 (0.72) GPR119CYP2C9
SCHEMBL386787 0.83 GPR119 (0.80) GPR119CYP2C9
SCHEMBL391379 0.82 GPR119 (0.69) GPR119CYP2C9
SCHEMBL1906298 0.82 GPR119 (0.71) GPR119CYP2C9
SCHEMBL389521 0.82 GPR119 (0.73) GPR119CYP2C9
SCHEMBL391698 0.82 GPR119 (0.68) GPR119CYP2C9
SCHEMBL389552 0.82 GPR119 (0.75) GPR119CYP2C9
SCHEMBL391292 0.81 GPR119 (0.77) GPR119CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1808168-B1 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level ARENA PHARM INC (US) 2009-06-03 EP disclosed